Sartorius Stedim Biotech releases Universal Registration Document 2023
Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Aubagne, February 16, 2024
Sartorius Stedim Biotech releases Universal Registration Document 2023 Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today. The document is available under the following link: https://ir-reports.sartorius.com/en/ssb/fy-2023. Financial calendar March 26, 2024 Annual General Meeting April 18, 2024 Publication of the quarterly figures January to March 2024 July 19, 2024 Publication of the half-year figures January to June 2024 October 17, 2024 Publication of the nine-month figures January to September 2024 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe. Contact Timo Lindemann External Communications +49 (0)551.308.4724 [email protected] Follow Sartorius on LinkedIn. Attachment File: Press Release
Dissemination of a Financial Wire News, transmitted by EQS Group. |
Language: | English |
Issuer: | Sartorius Stedim Biotech SA |
Avenue de Jouques | |
13781 Aubagne | |
France | |
Phone: | +33 44 284 5600 |
E-mail: | [email protected] |
Internet: | www.sartorius-stedim.com |
ISIN: | FR0013154002 |
EQS News ID: | 1838423 |
End of Announcement - EQS News Service |
|
1838423 16-Feb-2024 CET/CEST
Sartorius Stedim Biotech S.A. Aktie
189,30 €
-0,21 %